Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent

Prince of Songkla University70 enrolled

Overview

The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure. This transient, short-term intraocular pressure elevation (lasting up to 30 minutes) after intravitreal anti-vascular endothelial growth factor therapy has been well describe. The investigators aim to study the prevalence of the sustained intraocular pressure elevation associated with intravitreal injection of anti-vascular endothelial growth factor agents.

Intravitreal injections of anti-vascular endothelial growth factor agents are commonly used to treat a variety of retinal and choroidal neovascular diseases. The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure. Although there is one study showed no significant changes in the intraocular pressure many retrospective studies showed the impacts on the intraocular pressure elevation. The investigators aim to prospective evaluate the intraocular pressure change in non-glaucomatous patients receiving an intravitreal anti-vascular endothelial growth factor therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Intraocular Pressure

Interventions

Intravitreal injection (bevacizumab or ranibizumab)DRUG

The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients scheduled to receive intravitreal injection of anti-vascular endothelial growth factor agent (either bevacizumab or ranibizumab), and * Age of 18-85 year-old, and * Initial intraocular pressure \< 21 mmHg Exclusion Criteria: * Diagnosis of open angle, or * Diagnosis of angle-closure glaucoma, or * Diagnosis of glaucoma suspect (intraocular pressure \> 21 mmHg on 2-consecutive visit and/or cup to disc ratio \> 0.5) , or * Currently receive systemic beta-blocker * Previously received intravitreal injection of anti-vascular endothelial growth factor agent * Previously received intravitreal injection of steroid or gancyclovir * Current use of steroid eye drop * Any ocular surface disease preclude a reliable intraocular pressure measurement

Locations (1)

Weerawat Kiddee

Hat Yai, Changwat Songkhla, Thailand

Outcomes

Primary Outcomes

Change from baseline in intraocular pressure

intraocular pressure change at 6-month after injection

Time frame: 6-month after injection

Secondary Outcomes

Number of anti-glaucoma used

Start anti-glaucoma If there is an increase in intraocular pressure over the target IOP

Time frame: 6-month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.